Tag:
Astellas Pharma
Latest Headlines
Latest Headlines
Astellas, biotech VCs to pump $14M into virtual drug developer
Astellas and venture firms Interwest Partners and Sutter Hill Ventures plan to invest $14 million into a startup called Telsar Pharma.
Aveo on a hiring spree as it preps for the launch of tivozanib
The fast-growing developer tells The Boston Globe that it plans to hire 120 new staffers this year in preparation for the likely upcoming launch of tivozanib.
Pharma groups stand out in social media realm
According to a Pharmalot report, Astellas Pharma of Japan made a 1,100% jump in social media buzz from last week to the previous week.
Astellas, Lilly grab social-media limelight
Social media buzz can be both good and bad, and smart companies want to keep track of both.
After Astellas fallout, Zogenix strikes deal with Battelle to market DosePro
The company has wasted little time finding another marketing partner, inking a one-year deal with Battelle to promote the needle-free platform.
Astellas extends Lipitor marketing deal with Pfizer
Astellas Pharma extended its deal with Pfizer ($PFE) to market the cholesterol drug Lipitor in Japan.
Optimer inks $90M C. difficile drug pact with Astellas
Optimer is pocketing a $20 million up-front payment on a new commercial pact for its treatment for C. difficile.
Judge: No 1st Amendment shield for Astellas' Prograf petition
Japan's Astellas Pharma has to fight antitrust claims related to its transplant drug Prograf. The drugmaker failed to persuade a U.S. judge to dismiss consumer allegations it petitioned the FDA about
Scoring winners and losers in Japan pharma M&A bout
Japan's biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings. Now The
Astellas scores highest in Japanese M&A bout
Japan’s biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings.
